Nedosiran Sodium Patent Expiration

Nedosiran Sodium is used for treating Primary Hyperoxaluria Type 1 (PH1). It was first introduced by Novo Nordisk Inc in its drug Rivfloza on Sep 29, 2023.


Nedosiran Sodium Patents

Given below is the list of patents protecting Nedosiran Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Rivfloza US10351854 Therapeutic inhibition of lactate dehydrogenase and agents therefor Oct 09, 2035 Novo
Rivfloza US10738311 Therapeutic inhibition of lactate dehydrogenase and agents therefor Oct 09, 2035 Novo
Rivfloza US11053502 Therapeutic inhibition of lactate dehydrogenase and agents therefor Oct 29, 2035 Novo
Rivfloza US11286488 Methods and compositions for inhibiting expression of LDHA Oct 12, 2038 Novo
Rivfloza US11359203 Therapeutic inhibition of lactate dehydrogenase and agents therefor Oct 09, 2035 Novo
Rivfloza US11661604 Methods and compositions for inhibiting expression of LDHA Oct 12, 2038 Novo


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nedosiran Sodium's patents.

Given below is the list recent legal activities going on the following patents of Nedosiran Sodium.

Event Date Patent/Publication
Patent litigations
Mail Patent eCofC Notification 16 Jul, 2024 US11286488
Email Notification 16 Jul, 2024 US11286488
Patent eCofC Notification 16 Jul, 2024 US11286488
Recordation of Patent eCertificate of Correction 16 Jul, 2024 US11286488
Post Issue Communication - Certificate of Correction 12 Jul, 2024 US11661604
Mail Pub Notice re 312 amendment 01 Jul, 2024 US11661604
Email Notification 01 Jul, 2024 US11661604
POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION 26 Jun, 2024 US11661604
Post Issue Communication - Certificate of Correction Denied 26 Jun, 2024 US11661604
Post Issue Communication - Certificate of Correction 25 Jun, 2024 US11286488



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳